Heart failure at the crossroads: moving beyond blaming stakeholders to targeting the heart
暂无分享,去创建一个
[1] Giuseppe Ambrosio,et al. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. , 2014, European heart journal.
[2] M. Gheorghiade,et al. Molecular and Cellular Basis of Viable Dysfunctional Myocardium , 2014, Circulation. Heart failure.
[3] L. Tavazzi,et al. In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry. , 2014, International journal of cardiology.
[4] Naoki Sato,et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. , 2014, Journal of the American College of Cardiology.
[5] Sanjiv J. Shah,et al. Developing therapies for heart failure with preserved ejection fraction: current state and future directions. , 2014, JACC. Heart failure.
[6] J. Butler,et al. Patient-reported selective adherence to heart failure self-care recommendations: a prospective cohort study: the Atlanta Cardiomyopathy Consortium. , 2013, Congestive heart failure.
[7] G. Filippatos,et al. A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial , 2012, Heart Failure Reviews.
[8] J. Cleland,et al. Prevalence of scarred and dysfunctional myocardium in patients with heart failure of ischaemic origin: A cardiovascular magnetic resonance study , 2011, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.
[9] H. Krumholz,et al. Telemonitoring in patients with heart failure. , 2010, The New England journal of medicine.
[10] Elizabeth Avery,et al. Self-management counseling in patients with heart failure: the heart failure adherence and retention randomized behavioral trial. , 2010, JAMA.
[11] T. Trikalinos,et al. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. , 2010, Journal of the American College of Cardiology.
[12] B. Pitt,et al. Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Evaluating the Effect of Aldosterone Antagonism With Eplerenone on Ventricular Remodeling in Patients With Mild-to-Moderate Heart Failure and Left Ventricular Systolic Dysfunction , 2010, Circulation. Heart failure.
[13] P. Ponikowski,et al. Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes: Lessons Learned and Directions Forward , 2010, Circulation. Heart failure.